Abstract:
Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R and R are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR , (c) -NR R , (d) -NR SO2R , (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
Abstract translation:具有式(I)的化合物,其中W在每次出现时相同,并且选自任选取代的喹啉基,任选取代的苯并噻唑基,任选取代的苯并恶唑基,任选取代的苯并咪唑基,任选取代的喹喔啉基,任选取代的吡啶基,任选取代的嘧啶基, 噻唑基; R 1和R 2独立地选自氢,烷基,卤代烷基,烷氧基,卤素; R 3是价键或选自氢和烷基; X是价键或选自亚烷基,烯基和亚炔基; 并且Z选自(a)COM,(b)CH = NOA-COM,(c)CH2-ON = A-COM其中A选自亚烷基和亚环烷基,M选自(a)药学上可接受的代谢 可裂解基团,(b)-OR 6,(c)-NR 7 R 8,(d)-NR 6 SO 2 R 9,(e)-NH-四唑基和(f) 甘氨酰抑制白三烯生物合成,可用于治疗过敏性和炎性疾病状态。 还公开了白三烯生物合成抑制组合物和抑制白三烯生物合成的方法。
Abstract:
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein W is selected from the group consisting of optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R and R are one or more groups independently selected from hydrogen, alkyl, haloalkyl, alkoxy, and halogen; Z is selected from the group consisting of N-OH, N-O-A-COM, CH-COM, and CH-CH=N-O-A-COM wherein A is selected from the group consisting of alkylene, alkenylene, cycloalkylene, and optionally substituted alkylphenyl wherein the alkyl portion is of one to six carbon atoms, and M is selected from the group consisting of a pharmaceutically acceptable, metabolically cleavable group, -OR , and -NR R , inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
Abstract translation:具有式(I)化合物或其药学上可接受的盐,其中W选自任选取代的喹啉基,任选取代的苯并噻唑基,任选取代的苯并恶唑基,任选取代的苯并咪唑基,任选取代的喹喔啉基,任选取代的吡啶基,任选取代的嘧啶基,和 任选取代的噻唑基; R 1和R 2是一个或多个独立地选自氢,烷基,卤代烷基,烷氧基和卤素的基团; Z选自N-OH,NOA-COM,CH-COM和CH-CH = NOA-COM,其中A选自亚烷基,亚烯基,亚环烷基和任选取代的烷基苯基,其中烷基 部分为1至6个碳原子,M选自药学上可接受的,代谢可裂解基团-OR 3和-NR 4 R 5,抑制白三烯生物合成,并且可用于 治疗过敏和炎症疾病状态。 还公开了白三烯生物合成抑制组合物和抑制白三烯生物合成的方法。
Abstract:
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein W and Y at each occurrence are the same and W is selected from the group consisting of optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; Y is selected from optionally substituted phenylene and optionally substituted (c) wherein the alkylene portion is of one to six carbon atoms; A is selected from alkylene, alkenylene, cycloalkylene, and optionally substituted (d) wherein the alkylene portion is of one to six carbon atoms: and M is selected from hydrogen, a pharmaceutically acceptable cation, a metabolically cleavable group, -OR , and -NR R , inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis in a mammal.
Abstract:
Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R?1 and R2¿ are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH¿2?-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR?6¿, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
Abstract:
Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R?1 and R2¿ are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH¿2?-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR?6¿, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.